StockNews.com began coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the stock.
BiondVax Pharmaceuticals Price Performance
Shares of BVXV opened at $1.81 on Friday. BiondVax Pharmaceuticals has a 1 year low of $1.70 and a 1 year high of $13.90. The company has a debt-to-equity ratio of 5.92, a current ratio of 4.28 and a quick ratio of 6.15. The company has a market capitalization of $3.38 million, a price-to-earnings ratio of -0.51 and a beta of 2.47. The business has a 50-day moving average of $1.98 and a 200-day moving average of $4.00.
BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last issued its quarterly earnings data on Monday, April 17th. The company reported ($0.30) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On BiondVax Pharmaceuticals
BiondVax Pharmaceuticals Company Profile
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza.
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.